Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF 14.46
+0.46 (3.29%)
Jul 21, 2025, 5:38 PM CET
Santhera Pharmaceuticals Holding AG Company Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.
The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy.
Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.
Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Santhera Pharmaceuticals Holding AG
| Country | Switzerland |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Dario Eklund |
Contact Details
Address: Hohenrainstrasse 24 Pratteln, 4133 Switzerland | |
| Phone | 41 61 906 89 50 |
| Website | santhera.com |
Stock Details
| Ticker Symbol | SANN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0027148649 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dario Eklund | Chief Executive Officer |
| Dr. Thomas Meier Ph.D. | Founder and Chairman |
| Shabir Hasham M.D. | Chief Medical Officer |
| Geert Jan van Daal M.D., Ph.D. | Chief Commercial Officer |
| Catherine Ann Isted A.C.M.A. | Chief Financial Officer |
| Marc Schrader | Chief Technology Officer |
| Oliver Strub | Head of Compliance |
| Dr. Oliver P. Kronenberg Ph.D. | Chief Legal Officer and Corporate Secretary |
| Neville Kodkani M.D. | Head of Global Marketing and Partner Management |
| Sarah Holmes-Klotz | Global Head of People and Culture |